What is STRM.BIO?
STRM.BIO operates as a specialized biotechnology entity dedicated to overcoming the traditional hurdles associated with gene therapy delivery. By leveraging the natural properties of extracellular vesicles, the company aims to create a more efficient, safer, and scalable delivery vehicle for therapeutic payloads. This approach addresses critical bottlenecks in the current landscape of rare disease treatment, where delivery precision remains a primary challenge for clinical efficacy.
The company's market position is bolstered by a strategic focus on modularity and safety, distinguishing its platform from conventional viral vector-based approaches. As the industry shifts toward more practical and patient-centric solutions, STRM.BIO's commitment to simplifying the administration and manufacturing of gene therapies provides a distinct competitive advantage in the life sciences sector.
How much funding has STRM.BIO raised?
STRM.BIO has raised a total of $8M across 1 funding round:
Seed
$8M
Seed (2026): $8M with participation from Boehringer Ingelheim Venture Fund, BlueBay Asset Management, Delos Capital, and RECORDATI
Key Investors in STRM.BIO
Boehringer Ingelheim Venture Fund
A venture arm of a global pharmaceutical leader that invests in pioneering science and disease-modifying therapeutics to redefine care standards.
Delos Capital
A specialized firm focused on transforming innovative biotech and medtech ideas into medical breakthroughs through strategic capital and global network support.
RECORDATI
An international pharmaceutical group with a century of experience in research and development, focusing on therapeutic areas including rare diseases and specialized medical devices.
What's next for STRM.BIO?
Looking ahead, the deployment of this major enterprise-level funding will likely center on scaling the company's manufacturing capabilities and advancing its lead candidates through rigorous pre-clinical validation. The strategic backing from a consortium of pharmaceutical and venture capital heavyweights suggests a clear path toward potential clinical trials and future partnership opportunities. As STRM.BIO continues to mature, the focus will remain on demonstrating the durability and safety of its EV-based delivery system in complex biological environments. The company is poised to become a pivotal player in the genetic medicine ecosystem, potentially setting new standards for how therapeutic agents are delivered to target tissues globally.
See full STRM.BIO company page
